bluebird bio's CHMP Response Lays Ground Work For Its First Gene Therapy Approval

경제뉴스 2019. 4. 12. 07:53
,

https://seekingalpha.com/article/4254073-bluebird-bios-chmp-response-lays-ground-work-first-gene-therapy-approval

 

bluebird bio's CHMP Response Lays Ground Work For Its First Gene Therapy Approval

bluebird bio's Zynteglo receives positive CHMP opinion for approval of Zynteglo to treat transfusion dependent beta-thalassemia patients. The European Commissio

seekingalpha.com

 

저작자표시

'경제뉴스' 카테고리의 다른 글

Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal  (0) 2019.06.18
당뇨병 이해하기. (정말 자세한 설명입니다)  (0) 2019.06.04
인보사, 종양원성 100%사멸… 293세포라 제외되진 않을 것  (0) 2019.04.12
The top 15 pharma companies by 2018 revenue  (0) 2019.04.10
Bluebird tees up its first gene therapy approval with Zynteglo thumbs-up in EU  (0) 2019.03.30
posted by 투자를 통해서 배우는 인생

티스토리툴바